Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Anavex Life Sciences (Nasdaq: AVXL) announced that the Executive Committee of its Board has mailed a letter to stockholders urging them to vote the WHITE proxy card “FOR” all six director nominees at the 2026 Annual Meeting of Stockholders.
The company launched VoteAnavex.com to provide information on the nominees and voting instructions. The letter outlines the financial, clinical, regulatory and healthcare expertise of nominees Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden. The Annual Meeting is scheduled for September 24, 2026, with a record date of July 31, 2026. Anavex has filed a definitive proxy statement and WHITE proxy card with the SEC and encourages stockholders to review these materials.
Anavex Life Sciences (Nasdaq: AVXL) has filed definitive proxy materials with the SEC for its 2026 Annual Meeting of Stockholders, scheduled for September 24, 2026, with stockholders of record on July 31, 2026 eligible to vote. The company is soliciting support for six independent director nominees and has recently refreshed its board, adding two new candidates, Gautam Patel and Adrian Senderowicz, so that, if elected, half the board will have changed since early 2026 and all directors will be independent.
Following the April 2026 termination of its former CEO, the board appointed Dr. Terrie Kellmeyer as interim CEO and is advancing lead drug oral blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome. An IND for early Alzheimer’s was opened in March 2026, with ADME and drug–drug interaction studies underway or planned. Blarcamesine holds Orphan Drug, Rare Pediatric Disease and Fast Track designations for Rett syndrome and Orphan Drug Designation for Fragile X syndrome. The company also disclosed a Nasdaq delinquency notice dated May 20, 2026 for a late Form 10-Q and has submitted a compliance plan while working to complete outstanding filings.
Summary not available.
Anavex Life Sciences (Nasdaq: AVXL) reported preliminary fiscal Q2 2026 results and a business update centered on its lead candidate ANAVEX®2-73 (blarcamesine) for early Alzheimer’s disease, Rett syndrome and Fragile X syndrome. For the quarter ended March 31, 2026, preliminary cash and equivalents were $127.4 million, up from $102.6 million at September 30, 2025, with management expecting this to fund operations into mid-to-late fiscal 2028.
Preliminary Q2 general and administrative expenses declined to $2.3 million from $2.6 million, and research and development expenses to $4.2 million from $9.9 million, mainly after completion of an ANAVEX® 3-71 schizophrenia trial and lower manufacturing costs. Preliminary net loss narrowed to $5.3 million, or $0.06 per share, from $11.2 million, or $0.13 per share, a year earlier. The company opened a U.S. IND for early Alzheimer’s disease, started a drug-drug interaction study, plans an ADME study in Q3 2026, aligned with FDA on an adult Rett Phase 3 protocol, and holds Orphan Drug and other designations in Rett and Fragile X. Anavex also submitted a plan on July 20, 2026 to regain compliance with Nasdaq Listing Rule 5250(c)(1). All figures are preliminary and subject to closing procedures.
Anavex Life Sciences (Nasdaq: AVXL) received an expected Nasdaq delinquency notification on May 20, 2026, for not timely filing its Form 10-Q for the quarter ended March 31, 2026.
The company has until July 20, 2026 to submit a compliance plan and states the notice has no immediate effect on its Nasdaq listing.
Anavex Life Sciences (Nasdaq: AVXL) appointed Terrie Kellmeyer, PhD, as interim CEO effective May 6, 2026, following the departure of prior CEO Christopher Missling on April 30, 2026 and a request for his board resignation. Dr. Kellmeyer will prioritize clinical, regulatory and operational strategy for the company’s CNS pipeline, including lead candidate oral blarcamesine. The company said it has a strong cash balance with no long-term debt and expects to file a Form 12b-25 to extend its Form 10-Q filing for the quarter ended March 31, 2026. A conference call and webcast will be scheduled with further details.
Anavex (Nasdaq: AVXL) reported new scientific findings linking autophagy dysfunction and synaptic pruning deficits in autism spectrum disorder (ASD) with mechanisms in Alzheimer’s disease (AD). These data reinforce the biological rationale for orally administered blarcamesine, a SIGMAR1 activator, and support advancing blarcamesine into pivotal clinical studies subject to further evaluation and regulatory review.
Clinical evidence cited includes Phase IIb/III AD results, Phase II/III Rett syndrome signals, and Phase II Parkinson’s disease dementia proof-of-concept.
Anavex Life Sciences (Nasdaq: AVXL) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. Management is scheduled to present on Tuesday, April 14, 2026 at 1:30 PM ET. A live audio webcast and same‑day archived edition will be available via the company website.
Anavex Life Sciences (Nasdaq: AVXL) provided a regulatory update on March 30, 2026: the company withdrew its EU marketing authorization application for oral blarcamesine in early Alzheimer’s disease and will gather additional data while continuing dialogue with the EMA and CHMP.
Anavex also submitted additional data to the U.S. FDA to discuss potential pathways toward an NDA for early Alzheimer’s disease and is engaging EU regulators for blarcamesine in Parkinson’s disease and rare disorders including Rett syndrome.
Anavex (Nasdaq: AVXL) withdrew its EU marketing authorization application for blarcamesine as an add-on therapy for early Alzheimer’s disease on March 25, 2026 after the EMA’s CHMP indicated it would not be in a position to issue a positive opinion.
The company said it will consider CHMP feedback, gather additional data, conduct further analyses, and continue clinical development while maintaining engagement with regulators and patient organizations.